17:24 , Sep 14, 2018 |  BC Week In Review  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
22:43 , Sep 13, 2018 |  BC Week In Review  |  Company News

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million. Sanofi...
22:19 , Sep 13, 2018 |  BC Extra  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
23:38 , Sep 6, 2018 |  BC Extra  |  Company News

Zealand brings in $205M for pipeline via Royalty Pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
21:26 , Jul 27, 2018 |  BioCentury  |  Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...
16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

AZ's Farxiga plus Onglyza non-inferior to Lantus in Phase IIIb for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Farxiga (Forxiga) dapagliflozin plus Onglyza saxagliptin met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 24 in a Phase IIIb trial to...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
16:50 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Mylan, Biocon get CRL for insulin glargine follow-on

Mylan N.V. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said they recently received a complete response letter from FDA for their follow-on of diabetes drug Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY). The partners said they...
23:08 , Jun 5, 2018 |  BC Extra  |  Company News

Mylan, Biocon get CRL for insulin glargine follow-on

Mylan N.V. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said they recently received a complete response letter from FDA for their follow-on of diabetes drug Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY). The partners said...
00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...